Literature DB >> 30252978

Quantitative Identification of Nonmuscle-Invasive and Muscle-Invasive Bladder Carcinomas: A Multiparametric MRI Radiomics Analysis.

Xiaopan Xu1, Xi Zhang1, Qiang Tian2, Huanjun Wang3, Long-Biao Cui4,5, Shurong Li3, Xing Tang4, Baojuan Li1, Jose Dolz6, Ismail Ben Ayed6, Zhengrong Liang7, Jing Yuan8, Peng Du1, Hongbing Lu1, Yang Liu1.   

Abstract

BACKGROUND: Preoperative discrimination between nonmuscle-invasive bladder carcinomas (NMIBC) and the muscle-invasive ones (MIBC) is very crucial in the management of patients with bladder cancer (BC).
PURPOSE: To evaluate the discriminative performance of multiparametric MRI radiomics features for precise differentiation of NMIBC from MIBC, preoperatively. STUDY TYPE: Retrospective, radiomics. POPULATION: Fifty-four patients with postoperative pathologically proven BC lesions (24 in NMIBC and 30 in MIBC groups) were included. FIELD STRENGTH/SEQUENCE: 3.0T MRI/T2 -weighted (T2 W) and multi-b-value diffusion-weighted (DW) sequences. ASSESSMENT: A total of 1104 radiomics features were extracted from carcinomatous regions of interest on T2 W and DW images, and the apparent diffusion coefficient maps. Support vector machine with recursive feature elimination (SVM-RFE) and synthetic minority oversampling technique (SMOTE) were used to construct an optimal discriminative model, and its performance was evaluated and compared with that of using visual diagnoses by experts. STATISTICAL TESTS: Chi-square test and Student's t-test were applied on clinical characteristics to analyze the significant differences between patient groups.
RESULTS: Of the 1104 features, an optimal subset involving 19 features was selected from T2 W and DW sequences, which outperformed the other two subsets selected from T2 W or DW sequence in muscle invasion discrimination. The best performance for the differentiation task was achieved by the SVM-RFE+SMOTE classifier, with averaged sensitivity, specificity, accuracy, and area under the curve of receiver operating characteristic of 92.60%, 100%, 96.30%, and 0.9857, respectively, which outperformed the diagnostic accuracy by experts. DATA
CONCLUSION: The proposed radiomics approach has potential for the accurate differentiation of muscle invasion in BC, preoperatively. The optimal feature subset selected from multiparametric MR images demonstrated better performance in identifying muscle invasiveness when compared with that from T2 W sequence or DW sequence only. LEVEL OF EVIDENCE: 3 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:1489-1498.
© 2018 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  bladder cancer; multiparametric MRI; muscle invasion prediction; support vector machine-based recursive feature elimination (SVM-RFE); synthetic minority oversampling technique (SMOTE); visual assessment

Year:  2018        PMID: 30252978     DOI: 10.1002/jmri.26327

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  22 in total

1.  A predictive nomogram for individualized recurrence stratification of bladder cancer using multiparametric MRI and clinical risk factors.

Authors:  Xiaopan Xu; Huanjun Wang; Peng Du; Fan Zhang; Shurong Li; Zhongwei Zhang; Jing Yuan; Zhengrong Liang; Xi Zhang; Yan Guo; Yang Liu; Hongbing Lu
Journal:  J Magn Reson Imaging       Date:  2019-04-13       Impact factor: 4.813

2.  MRI-based radiomics signature for pretreatment prediction of pathological response to neoadjuvant chemotherapy in osteosarcoma: a multicenter study.

Authors:  Haimei Chen; Xiao Zhang; Xiaohong Wang; Xianyue Quan; Yu Deng; Ming Lu; Qingzhu Wei; Qiang Ye; Quan Zhou; Zhiming Xiang; Changhong Liang; Wei Yang; Yinghua Zhao
Journal:  Eur Radiol       Date:  2021-03-30       Impact factor: 5.315

Review 3.  Application of radiomics in precision prediction of diagnosis and treatment of gastric cancer.

Authors:  Getao Du; Yun Zeng; Dan Chen; Wenhua Zhan; Yonghua Zhan
Journal:  Jpn J Radiol       Date:  2022-10-19       Impact factor: 2.701

4.  CT-based radiomics features analysis for predicting the risk of anterior mediastinal lesions.

Authors:  He Sui; Lin Liu; Xuejia Li; Panli Zuo; Jingjing Cui; Zhanhao Mo
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

5.  CT imaging-based machine learning model: a potential modality for predicting low-risk and high-risk groups of thymoma: "Impact of surgical modality choice".

Authors:  Ayten Kayi Cangir; Kaan Orhan; Yusuf Kahya; Hilal Özakıncı; Betül Bahar Kazak; Buse Mine Konuk Balcı; Duru Karasoy; Çağlar Uzun
Journal:  World J Surg Oncol       Date:  2021-05-11       Impact factor: 2.754

6.  Utility of first order MRI-Texture analysis parameters in the prediction of histologic grade and muscle invasion in urinary bladder cancer: a preliminary study.

Authors:  Abdul Razik; Chandan J Das; Raju Sharma; Sundeep Malla; Sanjay Sharma; Amlesh Seth; Deep Narayan Srivastava
Journal:  Br J Radiol       Date:  2021-04-29       Impact factor: 3.629

7.  Radiomics Signatures of Computed Tomography Imaging for Predicting Risk Categorization and Clinical Stage of Thymomas.

Authors:  Xihai Wang; Wei Sun; Hongyuan Liang; Xiaonan Mao; Zaiming Lu
Journal:  Biomed Res Int       Date:  2019-05-28       Impact factor: 3.411

8.  Clinical value of texture analysis in differentiation of urothelial carcinoma based on multiphase computed tomography images.

Authors:  Zihua Wang; Yufang He; Nianhua Wang; Ting Zhang; Hongzhen Wu; Xinqing Jiang; Lei Mo
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.817

9.  Deep Learning on Enhanced CT Images Can Predict the Muscular Invasiveness of Bladder Cancer.

Authors:  Gumuyang Zhang; Zhe Wu; Lili Xu; Xiaoxiao Zhang; Daming Zhang; Li Mao; Xiuli Li; Yu Xiao; Jun Guo; Zhigang Ji; Hao Sun; Zhengyu Jin
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

10.  The Effect of Heterogenous Subregions in Glioblastomas on Survival Stratification: A Radiomics Analysis Using the Multimodality MRI.

Authors:  Lulu Yin; Yan Liu; Xi Zhang; Hongbing Lu; Yang Liu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.